Results 121 to 130 of about 3,975 (165)

Adjunctive albuvirtide is associated with improved immune recovery in treatment-naive patients with advanced HIV disease receiving bictegravir/emtricitabine/tenofovir alafenamide: a retrospective propensity score-matched cohort study. [PDF]

Front Immunol
Zhu Y, Liu H, Wang Y, Wang Z, Cai L.
europepmc   +1 more source

B/F/TAF in people with both HIV-1 and hepatitis B: outcomes from the ALLIANCE open-label extension phase. [PDF]

AIDS Res Ther
Avihingsanon A, Leong CL, Hung CC, Kiertiburanakul S, Lee MP, D'Antoni ML, Madera S, Wang H, Hindman JT, Li T.   +9 more
europepmc   +1 more source

Correction: Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial. [PDF]

PLoS One
Sequera-Arquelladas S, Vivancos MJ, Vinuesa D, Collado A, Santos IL, Sorni P, Cabello-Clotet N, Montero M, Font CR, Terron A, Galindo MJ, Martinez O, Ryan P, Omar-Mohamed M, Albendín-Iglesias H, Javier R, Romero A, Vallecillos CG, Calleja MÁ, Hidalgo-Tenorio C.   +19 more
europepmc   +1 more source

Virologic Outcomes of Common First-Line Antiretroviral Regimens Among Adults with HIV - China, 2021-2023. [PDF]

China CDC Wkly
Jia H, Zhao Y, Guan Y, Liu J, Geng Y, Gan X, Liu Y.   +6 more
europepmc   +1 more source

Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study. [PDF]

AIDS
Pennetzdorfer N, Naik V, Montezuma-Rusca JM, Sklar P, Callebaut C, Margot NA.   +5 more
europepmc   +1 more source

Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens. [PDF]

AIDS
Marcelin AG, Soulie C, Wirden M, Gruber J, Prata Menezes N, Lim T, Barriere G, Descamps D, Charpentier C, Calvez V.   +9 more
europepmc   +1 more source

Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial. [PDF]

Lancet HIV
Naidoo A, Naidoo K, Letsoalo MP, Wasmann RE, Dorse G, Perumal R, Moosa MS, Osuala EC, Boodhram R, Chimukangara B, Wiesner L, Israelski D, Denti P, Rooney JF, Dooley KE, INSIGHT Study Team.   +15 more
europepmc   +1 more source

Evolution and forecasting of antiretroviral therapy utilisation in British Columbia: a population-level analysis of provincial drug treatment programme data, 2014-2024. [PDF]

BMJ Open
Lima VD, Mokhtari Jazi A, Montaner JSG.
europepmc   +1 more source

Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study). [PDF]

Infect Dis Ther
Gagliardini R, Caioli A, Fusto M, Ottou S, Forbici F, Fabeni L, Maggi F, Plazzi MM, De Zottis F, Bellagamba R, Paulicelli J, Mastrorosa I, Grilli E, Pinnetti C, Mazzotta V, Caldera R, Forcina G, Antinori A.   +17 more
europepmc   +1 more source